Primary sclerosing cholangitis: Epidemiology, natural history, and prognosis

被引:54
作者
Levy, Cynthia
Lindor, Keith D.
机构
[1] Mayo Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] Univ Florida, Div Gastroenterol Hepatol & Nutr, Gainesville, FL USA
[3] Mayo Fdn, Div Gastroenterol & Hepatol, Mayo Med Sch, Rochester, MN USA
关键词
primary sclerosing cholangitis; epidemiology; natural history; liver transplantation;
D O I
10.1055/s-2006-933560
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Primary sclerosing cholangitis is a progressive disease associated with significant morbidity and mortality that continues to draw attention from investigators worldwide. Epidemiologic studies indicate that its annual incidence. remains stable, although more asymptomatic cases are being diagnosed. Nevertheless, even asymptomatic cases can progress to end-stage liver disease, albeit at a highly variable rate. Moreover, patients are predisposed to several malignancies, especially cholanglocarcinoma, which contributes to their decreased survival. On the other hand, a subgroup of patients with the so-called small-duct variant may have a better prognosis, and those with overlap syndromes with autoimmune hepatitis may respond well to immunosuppressants. Otherwise, efficient treatment is not available for patients with primary sclerosing cholangitis. Thus, even though it occurs rarely, this disease is commonly an indication for liver transplantation. Fortunately, transplantation outcomes are excellent, with overall 5-year survival rates of approximately 80%.
引用
收藏
页码:22 / 30
页数:9
相关论文
共 94 条
[1]  
AADLAND E, 1987, SCAND J GASTROENTERO, V22, P655, DOI 10.3109/00365528709011139
[2]   International Autoimmune Hepatitis Group Report:: review of criteria for diagnosis of autoimmune hepatitis [J].
Alvarez, E ;
Berg, PA ;
Bianchi, FB ;
Bianchi, L ;
Burroughs, AK ;
Cancado, EL ;
Chapman, RW ;
Cooksley, WGE ;
Czaja, AJ ;
Desmet, VJ ;
Donaldson, RT ;
Eddleston, ALWF ;
Fainboim, L ;
Heathcote, J ;
Homberg, JC ;
Hoofnagle, JH ;
Kakumu, S ;
Krawitt, EL ;
Mackay, IR ;
MacSween, RNM ;
Maddrey, WC ;
Manns, MP ;
McFarlane, IG ;
zum Büschenfelde, KHM ;
Mieli-Vergani, G ;
Nakanuma, Y ;
Nishioka, M ;
Penner, E ;
Porta, G ;
Portmann, BC ;
Reed, WD ;
Rodes, J ;
Schalm, SW ;
Scheuer, PJ ;
Schrumpf, E ;
Seki, T ;
Toda, G ;
Tsuji, T ;
Tygstrup, N ;
Vergani, D ;
Zeniya, M .
JOURNAL OF HEPATOLOGY, 1999, 31 (05) :929-938
[3]   Small-duct primary sclerosing cholangitis: A long-term follow-up study [J].
Angulo, P ;
Maor-Kendler, Y ;
Lindor, KD .
HEPATOLOGY, 2002, 35 (06) :1494-1500
[4]   The immunobiology of primary sclerosing cholangitis [J].
Aoki, CA ;
Bowlus, CL ;
Gershwin, ME .
AUTOIMMUNITY REVIEWS, 2005, 4 (03) :137-143
[5]   Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community [J].
Bambha, K ;
Kim, WR ;
Talwalkar, J ;
Torgerson, H ;
Benson, JT ;
Therneau, TM ;
Loftus, EV ;
Yawn, BP ;
Dickson, ER ;
Melton, LJ .
GASTROENTEROLOGY, 2003, 125 (05) :1364-1369
[6]   Triple therapy with amantadine sulphate plus ribavirin and interferon-alpha in previously untreated patients with chronic hepatitis C: Results of a double-blind, placebo-controlled trial [J].
Berg, T ;
Kronenberger, B ;
Hinrichsen, H ;
Gerlach, T ;
Buggisch, P ;
Spengler, U ;
Goeser, T ;
Pape, G ;
Hopf, U ;
Zeuzem, S .
JOURNAL OF HEPATOLOGY, 2002, 36 :3-3
[7]   Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis:: A case-control study [J].
Bergquist, A ;
Glaumann, H ;
Persson, B ;
Broomé, U .
HEPATOLOGY, 1998, 27 (02) :311-316
[8]  
Bernstein CN, 2001, AM J GASTROENTEROL, V96, P1116
[9]   PRIMARY INTRAHEPATIC OBLITERATING CHOLANGITIS - A POSSIBLE VARIANT OF SCLEROSING-CHOLANGITIS [J].
BHATHAL, PS ;
POWELL, LW .
GUT, 1969, 10 (11) :886-&
[10]   Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis [J].
Björnsson, E ;
Boberg, KM ;
Cullen, S ;
Fleming, K ;
Clausen, OP ;
Fausa, O ;
Schrumpf, E ;
Chapman, RW .
GUT, 2002, 51 (05) :731-735